482 related articles for article (PubMed ID: 24559196)
1. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
2. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
[TBL] [Abstract][Full Text] [Related]
4. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
[No Abstract] [Full Text] [Related]
5. Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans.
Ben-Joseph R; Chen CC; De AP; Wade RL; Shah D
J Med Econ; 2014 Oct; 17(10):708-18. PubMed ID: 24888403
[TBL] [Abstract][Full Text] [Related]
6. Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.
White AG; LeCates J; Birnbaum HG; Cheng W; Roland CL; Mardekian J
J Opioid Manag; 2015; 11(3):199-210. PubMed ID: 25985805
[TBL] [Abstract][Full Text] [Related]
7. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.
White AG; Birnbaum HG; Rothman DB; Katz N
Appl Health Econ Health Policy; 2009; 7(1):61-70. PubMed ID: 19558195
[TBL] [Abstract][Full Text] [Related]
8. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
[TBL] [Abstract][Full Text] [Related]
9. Modeling the potential impact of abuse-deterrent opioids on medical resource utilization.
Yenikomshian MA; White AG; Carson ME; Jia ZB; Mendoza MR; Roland CL
J Med Econ; 2019 Oct; 22(10):1073-1079. PubMed ID: 31314616
[No Abstract] [Full Text] [Related]
10. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
[TBL] [Abstract][Full Text] [Related]
11. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
[TBL] [Abstract][Full Text] [Related]
12. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
13. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
[TBL] [Abstract][Full Text] [Related]
14. Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl.
Kirson NY; White AG; Birnbaum HG; Schiller M; Waldman T; Peterson K; Ben-Joseph RH; Berner T; Summers KH
J Med Econ; 2012; 15(1):87-95. PubMed ID: 22032675
[TBL] [Abstract][Full Text] [Related]
15. Decreasing use of controlled-release oxycodone: response to Morden et al, June 2008 Medical Care.
Katz MH; Kotabe S
Med Care; 2008 Sep; 46(9):1002. PubMed ID: 18725857
[No Abstract] [Full Text] [Related]
16. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
[TBL] [Abstract][Full Text] [Related]
17. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M
Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
[TBL] [Abstract][Full Text] [Related]
20. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
Butler SF; Cassidy TA; Chilcoat H; Black RA; Landau C; Budman SH; Coplan PM
J Pain; 2013 Apr; 14(4):351-8. PubMed ID: 23127293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
